Emeritus Professor Stephen Mahler
Emeritus Professor

Stephen Mahler

Email: 

Background

Professor Stephen Mahler is a Senior Group Leader at the Australian Institute for Bioengineering and Nanotechnology and Director of the Australian Research Council Training Centre for Biopharmaceutical Innovation (CBI), University of Queensland. Professor Mahler is a biotechnologist with a focus on R&D of recombinant-DNA derived protein biopharmaceuticals, drug delivery systems and nanomedicines. Professor Mahler has a record of translational research success and engages extensively with industry associated with the biomedical sciences both nationally and internationally.

Research within CBI covers three thematic research areas; discovery of new biopharmaceuticals, engineering cells for production of protein-based biopharmaceuticals and advanced manufacturing for industrial production. A current research interest is at the interface of the life sciences and materials science, using a synthetic biology approach for creating novel therapeutic entities as well as new systems for drug delivery.

Professor Mahler has a strong interest in education and training and was formerly Head of the Chemical and Biological Engineering Plan at the University of Queensland (2010-2016). Other educational initiatives include development of Masters Programs and a Continuing Professional Development program in the area of biopharmaceuticals. The CPD program is available to stakeholders in the industry, both in Australia and internationally.

Availability

Emeritus Professor Stephen Mahler is:
Available for supervision
Media expert

Fields of research

Biological Sciences Industrial biotechnology Medical biotechnology

Qualifications

  • Doctor of Philosophy, The University of Queensland

Research impacts

Professor Mahler has a strong engagement with industry both nationally and internationally, that through collaborative research has led to some significant translational outcomes including clinical trial of biopharmaceutical drug candidates through to approval. The Australian Research Council Training Centre for Biopharmaceutical Innovation is a consortium of partners including government, the University of Queensland and several industry partners, with a goal of contributing to the transformation of the biopharmaceutical industry. Through the Centre and the CPD Program in Biopharmaceuticals, Professor Mahler continues to work with stakeholders to ensure a vibrant future for the biopharmaceutical industry in Australia.

Search Professor Stephen Mahler’s works on UQ eSpace

144 works between 1984 and 2024
All (144) Journal Article (101) Book Chapter (20) Conference Publication (18) Other Outputs (5)

61 - 80 of 144 works

2016

Book Chapter

Interleukin-6 Inhibitor: Tocilizumab

Pile, Kevin D., Graham, Garry G. and Mahler, Stephen M. (2016). Interleukin-6 Inhibitor: Tocilizumab. Compendium of Inflammatory Diseases. (pp. 692-696) Springer Science+Business Media. doi: 10.1007/978-3-7643-8550-7_231

Interleukin-6 Inhibitor: Tocilizumab

2016

Book Chapter

Tumor Necrosis Factor (TNF) Inhibitors

Pile, Kevin D., Graham, Garry G. and Mahler, Stephen M. (2016). Tumor Necrosis Factor (TNF) Inhibitors. Compendium of Inflammatory Diseases. (pp. 1282-1290) Springer Science+Business Media. doi: 10.1007/978-3-7643-8550-7_67

Tumor Necrosis Factor (TNF) Inhibitors

2016

Book Chapter

Interleukin-12/23 Inhibitors: Ustekinumab

Pile, Kevin D., Graham, Garry G. and Mahler, Stephen M. (2016). Interleukin-12/23 Inhibitors: Ustekinumab. Compendium of Inflammatory Diseases. (pp. 714-717) Springer Science+Business Media. doi: 10.1007/978-3-7643-8550-7_232

Interleukin-12/23 Inhibitors: Ustekinumab

2016

Book Chapter

Interleukin-1 (IL-1) Inhibitors: Anakinra, Rilonacept, and Canakinumab

Pile, Kevin D., Graham, Garry G. and Mahler, Stephen M. (2016). Interleukin-1 (IL-1) Inhibitors: Anakinra, Rilonacept, and Canakinumab. Compendium of Inflammatory Diseases. (pp. 666-670) Springer Science+Business Media. doi: 10.1007/978-3-7643-8550-7_29

Interleukin-1 (IL-1) Inhibitors: Anakinra, Rilonacept, and Canakinumab

2015

Journal Article

Immunosuppressive human anti-CD83 monoclonal antibody depletion of activated dendritic cells in transplantation.

Seldon, T. A., Pryor, R., Palkova, A., Jones, M. L., Verma, N. D., Findova, M., Braet, K., Sheng, Y., Fan, Y., Zhou, Y. Y., Marks, J. D., Munro, T., Mahler, S. M., Barnard, R. T., Fromm, P. D., Silveira, P. A., Elgundi, Z., Ju, X., Clark, G. J., Bradstock, K. F., Munster, D. J. and Hart, D. N. J. (2015). Immunosuppressive human anti-CD83 monoclonal antibody depletion of activated dendritic cells in transplantation.. Leukemia, 30 (3), 692-700. doi: 10.1038/leu.2015.231

Immunosuppressive human anti-CD83 monoclonal antibody depletion of activated dendritic cells in transplantation.

2015

Journal Article

Effect of energy source, salt concentration and loading force on colloidal interactions between Acidithiobacillus ferrooxidans cells and mineral surfaces

Diao, Mengxue, Nguyen, Tuan A.H., Taran, Elena, Mahler, Stephen M. and Nguyen, Anh V. (2015). Effect of energy source, salt concentration and loading force on colloidal interactions between Acidithiobacillus ferrooxidans cells and mineral surfaces. Colloids and Surfaces B: Biointerfaces, 132, 271-280. doi: 10.1016/j.colsurfb.2015.05.026

Effect of energy source, salt concentration and loading force on colloidal interactions between Acidithiobacillus ferrooxidans cells and mineral surfaces

2015

Journal Article

Preparation of optimized lipid-coated calcium phosphate nanoparticles for enhanced in vitro gene delivery to breast cancer cells

Tang, Jie, Li, Li, Howard, Christopher B., Mahler, Stephen M., Huang, Leaf and Xu, Zhi Ping (2015). Preparation of optimized lipid-coated calcium phosphate nanoparticles for enhanced in vitro gene delivery to breast cancer cells. Journal of Materials Chemistry B, 3 (33), 6805-6812. doi: 10.1039/c5tb00912j

Preparation of optimized lipid-coated calcium phosphate nanoparticles for enhanced in vitro gene delivery to breast cancer cells

2015

Journal Article

Advances in drug delivery

Mahler, Stephen and Roy, Ipsita (2015). Advances in drug delivery. Journal of Chemical Technology and Biotechnology, 90 (7), 1167-1168. doi: 10.1002/jctb.4689

Advances in drug delivery

2015

Journal Article

Production and characterisation of recombinant human chaperonin 10 for treatment of inflammatory disease

Naylor, Dean J., Hunt, Ben, Guidolin, Angelo, Hey, Allan W., Bastiras, Stan, de Bakker, Christopher J., Chin, David Y., Marquis, Christopher P., Lambert, Daniel, Howard, Christopher B., Dobbin, Caroline A. and Mahler, Stephen M. (2015). Production and characterisation of recombinant human chaperonin 10 for treatment of inflammatory disease. Process Biochemistry, 50 (10) 10466, 1669-1679. doi: 10.1016/j.procbio.2015.06.022

Production and characterisation of recombinant human chaperonin 10 for treatment of inflammatory disease

2015

Conference Publication

The Human Monoclonal Antibody 3C12C, Targeting Activated Dendritic Cells Is a Potential New Immunosuppressive Agent

Verma, Nirupama D., Munster, David, Seldon, Therese, Sheng, Yong Hua, Jones, Martina, Munro, Trent, Mahler, Stephen, Barnard, Ross, Vu, Phi Ai, Lo, Kevin, Shahin, Kifah, Elgundi, Zehra, Silveira, Pablo, Fromm, Phillip D., Clark, Georgina J., Larsen, Stephen, Bradstock, Kenneth and Hart, Derek N. J. (2015). The Human Monoclonal Antibody 3C12C, Targeting Activated Dendritic Cells Is a Potential New Immunosuppressive Agent. BMT Tandem Meetings, San Diego, CA United States, 11-15 February 2015. Philadelphia, PA United States: Elsevier. doi: 10.1016/j.bbmt.2014.11.527

The Human Monoclonal Antibody 3C12C, Targeting Activated Dendritic Cells Is a Potential New Immunosuppressive Agent

2015

Book Chapter

TNF Inhibitors

Pile, Kevin D., Graham, Garry G. and Mahler, Stephen M. (2015). TNF Inhibitors. Encyclopedia of Inflammatory Diseases. (pp. 1-10) edited by Michael J. Parnham. Basel Switzerland: Springer. doi: 10.1007/978-3-0348-0620-6_67-1

TNF Inhibitors

2015

Book Chapter

Interleukin 1 Inhibitors

Pile, Kevin D., Graham, Garry G. and Mahler, Stephen M. (2015). Interleukin 1 Inhibitors. Encyclopedia of Inflammatory Diseases. (pp. 1-5) edited by Michael J. Parnham. Basel Switzerland: Springer. doi: 10.1007/978-3-0348-0620-6_29-1

Interleukin 1 Inhibitors

2015

Book Chapter

CD20 Inhibitors: Rituximab

Pile, Kevin D., Graham, Garry G. and Mahler, Stephen M. (2015). CD20 Inhibitors: Rituximab. Encyclopedia of Inflammatory Diseases. (pp. 1-4) edited by Michael J. Parnham. Basel Switzerland: Springer. doi: 10.1007/978-3-0348-0620-6_21-1

CD20 Inhibitors: Rituximab

2015

Conference Publication

Human Cd83 Expression On Immune Cells Validates Anti-Cd83 Prophylaxis to Prevent Graft Versus Host Disease in Allogeneic Haematopoietic Cell Transplantation.

Ju, Xinsheng, Elgundi, Zehra, Verma, Nirupama, Silveira, Pablo, Fromm, Phillip, Alingcastre, Renz, Munster, David, Seldon, Therese, Sheng, Yonghua, Jones, Martina, Munro, Trent, Mahler, Stephen, Barnard, Ross, Vu, Ai, Lo, Tsun Ho, Shahin, Kifah, Clark, Georgina, Larsen, Stephen, Bradstock, Kenneth and Hart, Derek (2015). Human Cd83 Expression On Immune Cells Validates Anti-Cd83 Prophylaxis to Prevent Graft Versus Host Disease in Allogeneic Haematopoietic Cell Transplantation.. 14th Transplantation Science Symposium of the Transplantation-Society (TSS), Lorne, Australia, 11-13 November 2015. PHILADELPHIA: LIPPINCOTT WILLIAMS & WILKINS.

Human Cd83 Expression On Immune Cells Validates Anti-Cd83 Prophylaxis to Prevent Graft Versus Host Disease in Allogeneic Haematopoietic Cell Transplantation.

2015

Book Chapter

Disease-Modifying Anti-Rheumatic Drugs

Pile, Kevin D., Graham, Garry G. and Mahler, Stephen M. (2015). Disease-Modifying Anti-Rheumatic Drugs. Encyclopedia of Inflammatory Diseases. (pp. 1-13) edited by Michael J. Parnham. Basel Switzerland: Springer. doi: 10.1007/978-3-0348-0620-6_48-1

Disease-Modifying Anti-Rheumatic Drugs

2015

Book Chapter

CD80/CD86 Inhibitors

Pile, Kevin D., Graham, Garry G. and Mahler, Stephen M. (2015). CD80/CD86 Inhibitors. Encyclopedia of Inflammatory Diseases. (pp. 1-4) edited by Michael J. Parnham. Basel Switzerland: Springer. doi: 10.1007/978-3-0348-0620-6_20-1

CD80/CD86 Inhibitors

2015

Book Chapter

Interleukin-6 Inhibitor – Tocilizumab

Pile, Kevin D., Graham, Garry G. and Mahler, Stephen M. (2015). Interleukin-6 Inhibitor – Tocilizumab. Encyclopedia of Inflammatory Diseases. (pp. 1-5) edited by Michael J. Parnham. Basel Switzerland: Springer. doi: 10.1007/978-3-0348-0620-6_231-1

Interleukin-6 Inhibitor – Tocilizumab

2015

Conference Publication

CD83 Expression On Human Immune Cells as a Target for Immunosuppression

Hart, D. N. J., Elgundi, Z., Ju Xinsheng, Verma, N. D., Silveira, P. A., Fromm, P. D., Alingcastre, R., Munster, D. J., Seldon, T. A., Sheng, Y., Jones, M. L., Munro, T. P., Mahler, S., Barnard, R. T., Vu, P. A., Lo, K., Shahin, K., Larsen, S., Bradstock, K. and Clark, G. J. (2015). CD83 Expression On Human Immune Cells as a Target for Immunosuppression. 33rd Annual Scientific Meeting of the Transplantation Society of Australia and new Zealand, Canberra, ACT Australia, 21-23 June 2015. London, United Kingdom: Nature Publishing Group. doi: 10.1038/icb.2015.75

CD83 Expression On Human Immune Cells as a Target for Immunosuppression

2015

Conference Publication

Characterisation of human CD83 expression on immune cells and their targeting with CD83 antibodies to prevent graft versus host disease in allogeneic haematopoietic cell transplantation

Hart, Derek N. J., Ju, Xinsheng, Elgundi, Zehra, Verma, Nirupama, Silveira, Pablo, Fromm, Phillip, Alingcastre, Renz, Hsu, Blake, Munster, David J., Seldon, Therese, Sheng, Yonghua, Jones, Martina, Munro, Trent, Mahler, Stephen, Barnard, Ross, Vu, Al, Lo, Tsun Ho, Shahin, Kifah, Larsen, Stephen Robert, Bradstock, Kenneth and Clark, Georgina (2015). Characterisation of human CD83 expression on immune cells and their targeting with CD83 antibodies to prevent graft versus host disease in allogeneic haematopoietic cell transplantation. 57th Annual Meeting of the American Society of Hematology, Orlando, FL, United States, 5-8 Dec 2015. WASHINGTON: AMER SOC HEMATOLOGY.

Characterisation of human CD83 expression on immune cells and their targeting with CD83 antibodies to prevent graft versus host disease in allogeneic haematopoietic cell transplantation

2014

Journal Article

Nanocell targeting using engineered bispecific antibodies.

Taylor, Karin, Howard, Christopher B., Jones, Martina L., Sedliarou, Ilya, MacDiarmid, Jennifer, Brahmbhatt, Himanshu, Munro, Trent P. and Mahler, Stephen M. (2014). Nanocell targeting using engineered bispecific antibodies.. mAbs, 7 (1), 53-65. doi: 10.4161/19420862.2014.985952

Nanocell targeting using engineered bispecific antibodies.

Past funding

  • 2021 - 2023
    ACRF Facility for Targeted Radiometals in Cancer (AFTRiC)
    Australian Cancer Research Foundation
    Open grant
  • 2020 - 2021
    An integrated, multi-node bio-layer interferometry facility
    ARC Linkage Infrastructure, Equipment and Facilities
    Open grant
  • 2019 - 2022
    Smart affinity membranes for manufacture of high value therapeutic proteins
    ARC Linkage Projects
    Open grant
  • 2019
    A versatile accurate mass, high resolution QTOF mass spectrometer for chemistry and proteomic applications
    UQ Major Equipment and Infrastructure
    Open grant
  • 2019
    Advanced Nanoparticle, Colloid and Microparticle Characterisation and Precision Engineering Nanosystems Facility
    UQ Major Equipment and Infrastructure
    Open grant
  • 2019
    Cyto-Mine to accelerate Cell Line Development for Vaccines and Biopharmaceuticals
    UQ Major Equipment and Infrastructure
    Open grant
  • 2019 - 2021
    Nanomedicine strategies for early detection and treatment of brain metastases
    NHMRC Project Grant
    Open grant
  • 2018
    Continuous chromatography system for advanced bioprocessing
    UQ Major Equipment and Infrastructure
    Open grant
  • 2018
    In vivo optical imaging into the next generation
    UQ Research Facilities Infrastructure Grants
    Open grant
  • 2017 - 2018
    Affinity Maturation of Anti-Lipopolysaccharide Antibody
    Innovation Connections
    Open grant
  • 2017 - 2018
    Provision of research services to Minomic International Ltd
    Minomic International Ltd
    Open grant
  • 2017 - 2023
    ARC Training Centre for Biopharmaceutical Innovation
    ARC Industrial Transformation Training Centres
    Open grant
  • 2016 - 2017
    EGFR targeted nanoparticle feasibility study
    Samyang Biopharmaceuticals Corporation
    Open grant
  • 2016 - 2019
    Next generation hybrid nanomaterials: bispecific antibody-targeted polymers
    ARC Linkage Projects
    Open grant
  • 2016 - 2017
    The biophysical characterisation of novel, recombinant bi-specific antibodies utilised in drug-delivery technology using Bio-layer Interferometry (Octet).
    Research Connections
    Open grant
  • 2016
    Exosome and Bio/Nanoparticle Characterisation Facility
    UQ Major Equipment and Infrastructure
    Open grant
  • 2016 - 2018
    Immuno-polymeric drugs for prostate cancer therapy
    NHMRC Project Grant
    Open grant
  • 2015
    A sensitive, high resolution QTOF mass spectrometer with nanoUPLC system for qualitative and quantitative biomolecule analysis.
    UQ Major Equipment and Infrastructure
    Open grant
  • 2015 - 2016
    Developing targeted EphA2 based imaging technology for glioblastoma
    Cure Brain Cancer Foundation
    Open grant
  • 2014 - 2023
    The National Biologics Facility - NCRIS 2013/2015/2016-17/2017-18/2018-19/2019-2023 (administered by Therapeutic Innovation Australia (TIA))
    Therapeutic Innovation Australia Limited
    Open grant
  • 2013 - 2015
    Safety assessment of anti-hendra virus antibody in humans
    Queensland Health
    Open grant
  • 2013
    QM6 Process Investigations
    UniQuest Pty Ltd
    Open grant
  • 2012 - 2015
    Single molecule spectroscopy-guided design of thermostable industrial enzymes
    ARC Linkage Projects
    Open grant
  • 2012 - 2015
    The first integrated multimodal assay for the ultrasensitive detection of dengue contamination of blood
    ARC Linkage Projects
    Open grant
  • 2012 - 2013
    Safety of Hendra virus anti-G glycoprotein monoclonal antibody in humans
    NHMRC Targeted Research
    Open grant
  • 2012 - 2015
    Targeting the delivery of cytotoxic agents to tumour cells using novel minicells as drug delivery vehicles and engineered, bispecific antibodies
    ARC Linkage Projects
    Open grant
  • 2011
    Mass spectrometer for biomolecule discovery, structural analysis and quantification.
    UQ Major Equipment and Infrastructure
    Open grant
  • 2010 - 2012
    Development of an integrated technology platform for neural cell surface marker discovery and characterisation
    UQ Collaboration and Industry Engagement Fund
    Open grant
  • 2010 - 2013
    Development of chaperonin 10-based second generation biopharmaceuticals for treatment of inflammatory diseases
    ARC Linkage Projects
    Open grant
  • 2010 - 2011
    High throughput isolation and expression of recombinant antibodies in mammalian cells
    UQ FirstLink Scheme
    Open grant
  • 2010
    Cost effective acquisition of an LC-MS/MS system to support CIPDD organics analysis and preclinical and clinical operations
    UQ Major Equipment and Infrastructure
    Open grant
  • 2009
    Robotics Instrumentation for High Throughput Sample preparation for Increased Productivity of the CIPDD/TetraQ's HPLC-MS/MS Systems for Quantitative Analysis of Organics in a Quality Systems NATA-Acc
    UQ Faculty Co-Funding
    Open grant
  • 2009
    Stem cell-based interface tissue engineering
    ARC Discovery Projects
    Open grant

Availability

Emeritus Professor Stephen Mahler is:
Available for supervision

Before you email them, read our advice on how to contact a supervisor.

Supervision history

Current supervision

  • Doctor Philosophy

    Biosimilar litigation and market entry

    Associate Advisor

    Other advisors: Professor Avril Robertson

  • Doctor Philosophy

    Engineering Novel Theranostics for High Grade Glioma Through Site-Specific EphA2 Antibody Modification

    Associate Advisor

    Other advisors: Dr Christopher Howard, Dr Martina Jones

Completed supervision

Enquiries

Contact Emeritus Professor Stephen Mahler directly for media enquiries about:

  • Antibodies
  • Biologic medicines
  • Pharmaceuticals

Need help?

For help with finding experts, story ideas and media enquiries, contact our Media team:

communications@uq.edu.au